Healthcare / BiotechnologyNasdaqCM
$3.44
-0.16 (-4.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-34.6M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$263M
P/E
N/A
•EV/EBITDA
9.6x
↓ROE
8.8%
↑Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-3.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $13.3M · FCF $-45.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $60.9M | $55.2M |
| Net Income | $13.3M | $13.3M | $-34.1M | $-42.2M | $-18.7M | $-17.1M | $20.1M |
| EBITDA | $16.6M | $16.6M | $-29.0M | $-38.1M | $-15.1M | $-11.9M | $20.9M |
| EPS | — | — | -3.68 | -7.64 | -4.31 | -6.30 | 7.40 |
| Operating Margin | — | — | — | — | — | -22.0% | 37.2% |
| Net Margin | — | — | — | — | — | -28.2% | 36.4% |
| Balance Sheet | |||||||
| Debt/Equity | 0.04 | 0.04 | 0.18 | 0.10 | 0.19 | — | — |
| Current Ratio | 11.45 | 11.45 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-45.7M | $-45.7M | $-34.6M | $-25.3M | $-25.6M | $-9.0M | $-2.7M |
| Returns | |||||||
| ROE | 8.8% | 8.8% | -131.3% | -73.6% | -60.3% | -44.5% | 51.6% |
| Valuation | |||||||
| EV/EBITDA | 9.59 | 9.59 | — | — | — | — | — |
| P/B | 1.08 | 1.08 | 1.31 | 0.56 | 0.85 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | 10.2% | — |
| EPS Growth | — | — | 51.8% | -77.3% | — | -185.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.68 → n/d
Residual
+78.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.